Investors

Event Calendar

 

Upcoming Events

Obseva 2023 Swiss Annual Report: 30 April, 2024

Read more


    Annual General Meeting: Thursday 27 June, 2024

    Venue: TBC // Registration Deadline: Thursday 13 June 2024
    Read more


      Half Year 2024 Financial Results: 30 September 2024

      Read more


        Past Events

        Year End 2022 Financial Results 31 March 2023

        April 1, 2023

        Read more

        Q3 2022 Financial Results Thursday 1st December, 2022

        December 4, 2022

        Read more

        Q2 2022 Financial Results week of 15 August 2022

        August 12, 2022

        Read more
        1 2 3 4 32

        General Meetings

        ObsEva Extraordinary General Meeting 2018

        January 28, 2018

        Read more

        ObsEva Annual General Meeting 2017

        June 13, 2017

        Read more
        1 2 3 4
         
         

        Sign up for news

         
         

          * Type:


          InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












          Read our privacy policy here.


           

          Are you sure you want to leave ObsEva.com?

          We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

          Continue to link

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue

          Disclaimer

          Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

          Continue